Pfizer – Chronic myeloid leukemia

Access Program Information

<p>The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.</p>